For research use only. Not for therapeutic Use.
Nedometinib(CAT: I040773) is a potent and selective inhibitor of MEK1/2 (mitogen-activated protein kinase kinases 1 and 2), key components of the RAS-RAF-MEK-ERK signaling pathway, which regulates cell proliferation, survival, and differentiation. By targeting MEK1/2, Nedometinib blocks downstream ERK activation, leading to the suppression of tumor cell growth and survival. This compound is being explored as a targeted therapy for cancers driven by aberrant RAS or RAF mutations, such as melanoma, colorectal cancer, and non-small cell lung cancer (NSCLC). Nedometinib is a valuable tool in cancer research and drug development focused on MAPK pathway inhibition and precision oncology.
| CAS Number | 2252314-46-6 |
| Synonyms | 2-(2-fluoro-4-iodoanilino)-N-(2-hydroxyethoxy)-1-methylpyrrolo[2,3-b]pyridine-3-carboxamide |
| Molecular Formula | C17H16FIN4O3 |
| Purity | ≥95% |
| IUPAC Name | 2-(2-fluoro-4-iodoanilino)-N-(2-hydroxyethoxy)-1-methylpyrrolo[2,3-b]pyridine-3-carboxamide |
| InChI | InChI=1S/C17H16FIN4O3/c1-23-15-11(3-2-6-20-15)14(17(25)22-26-8-7-24)16(23)21-13-5-4-10(19)9-12(13)18/h2-6,9,21,24H,7-8H2,1H3,(H,22,25) |
| InChIKey | SENAOZROGSYRTD-UHFFFAOYSA-N |
| SMILES | CN1C2=C(C=CC=N2)C(=C1NC3=C(C=C(C=C3)I)F)C(=O)NOCCO |
